Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 2/20 | 0.47 |
| ▸ | ECE1 | P42892 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.43 |
| ▸ | ACE | P12821 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16415834 | 0.88 | MME (0.49) | MMEECE1MEN1KMT2AL3MBTL1 | |
| SCHEMBL73701 | 0.87 | L3MBTL1 (0.46) | MMEECE1MEN1KMT2AL3MBTL1 | |
| Ammonia Solution, Strong SCHEMBL2415758 | 0.84 | MME (0.49) | MMEECE1MEN1KMT2AL3MBTL1 | |
| SCHEMBL43350 | 0.83 | MME (0.62) | MMEECE1MEN1KMT2AL3MBTL1 | |
| SCHEMBL43351 | 0.83 | MME (0.62) | MMEECE1MEN1KMT2AL3MBTL1 | |
| SCHEMBL8932450 | 0.79 | MME (0.47) | MMEECE1MEN1KMT2AACE | |
| SCHEMBL28236617 | 0.77 | L3MBTL1 (0.48) | MMEL3MBTL1NPSR1PTPN1 | |
| SCHEMBL31510352 | 0.77 | ANPEP (0.48) | MMEECE1MEN1KMT2AL3MBTL1 | |
| SCHEMBL7411127 | 0.77 | MME (0.62) | MMEECE1MEN1KMT2AACE | |
| SCHEMBL7411123 | 0.77 | MME (0.62) | MMEECE1MEN1KMT2AACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1994008600-A1 | INHIBITION OF SIGNAL TRANSDUCTION MOLECULES | JOSLIN DIABETES CENTER (US) | 1994-04-28 | — | — | WO | claimed |
| US-9937230-B2 | Ophthalmic uses of toxin-based therapeutic peptides and pharmaceutical compositions thereof | KINETA ONE, LLC (US) | 2018-04-10 | — | — | US | disclosed |
| US-20160338967-A1 | SUSTAINED RELEASE DEPOT FORMULATIONS OF THERAPEUTIC PROTEINS, AND USES THEREOF | KINETA ONE, LLC (US) | 2016-11-24 | — | — | US | disclosed |
| EP-3086779-A2 | SUSTAINED RELEASE DEPOT FORMULATIONS OF THERAPEUTIC PROTEINS, AND USES THEREOF | Kineta One, LLC (US) | 2016-11-02 | — | — | EP | disclosed |
| US-20160151457-A1 | OPHTHALMIC USES OF TOXIN-BASED THERAPEUTIC PEPTIDES AND PHARMACEUTICAL COMPOSITIONS THEREOF | KINETA ONE, LLC (US) | 2016-06-02 | — | — | US | disclosed |
| EP-3024472-A2 | OPHTHALMIC USES OF TOXIN-BASED THERAPEUTIC PEPTIDES AND PHARMACEUTICAL COMPOSITIONS THEREOF | Kineta One, LLC (US) | 2016-06-01 | — | — | EP | disclosed |
| WO-2015100370-A2 | SUSTAINED RELEASE DEPOT FORMULATIONS OF THERAPEUTIC PROTEINS, AND USES THEREOF | KINETA ONE, LLC (US) | 2015-07-02 | — | — | WO | disclosed |
| WO-2015013330-A2 | OPHTHALMIC USES OF TOXIN-BASED THERAPEUTIC PEPTIDES AND PHARMACEUTICAL COMPOSITIONS THEREOF | KINETA ONE, LLC (US) | 2015-01-29 | — | — | WO | disclosed |
| US-5801149-A | PEPTIDS FOR INHIBITION OF PROTEINS | JOSLIN D-ABETES CENTER, INC. (US) | 1998-09-01 | — | — | US | disclosed |
| WO-1994008600-A1 | INHIBITION OF SIGNAL TRANSDUCTION MOLECULES | JOSLIN DIABETES CENTER (US) | 1994-04-28 | — | — | WO | disclosed |